Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 247,444
  • Shares Outstanding, K 168,329
  • Annual Sales, $ 37,430 K
  • Annual Income, $ -251,120 K
  • 60-Month Beta -0.41
  • Price/Sales 6.70
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EPZM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.15
  • Most Recent Earnings -0.21 on 08/09/22
  • Next Earnings Date 08/08/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 +1.38%
on 08/04/22
1.5300 -3.92%
on 08/08/22
unch (unch)
since 07/11/22
3-Month
0.4110 +257.66%
on 06/01/22
1.5800 -6.96%
on 06/27/22
+1.0023 (+214.30%)
since 05/11/22
52-Week
0.4110 +257.66%
on 06/01/22
5.8000 -74.66%
on 09/09/21
-4.0100 (-73.18%)
since 08/11/21

Most Recent Stories

More News
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

BMRN : 112.20 (-0.57%)
EPZM : 1.4700 (-1.34%)
APTX : 0.4900 (+2.04%)
INZY : 2.86 (+16.73%)
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

NVAX : 11.23 (-6.49%)
EPZM : 1.4700 (-1.34%)
IPSEY : 25.8600 (-2.12%)
SESN : 0.5902 (+0.41%)
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 1.4700 (-1.34%)
MGTX : 8.12 (-2.75%)
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported...

EPZM : 1.4700 (-1.34%)
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

Regulatory News:

OTC.VN : 0.365 (-6.41%)
EPZM : 1.4700 (-1.34%)
IPN : 34.71 (-0.54%)
IPSEY : 25.8600 (-2.12%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

EPZM : 1.4700 (-1.34%)
LION : 8.62 (-7.31%)
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

WWE : 89.72 (+5.17%)
DRE : 48.20 (+0.48%)
MN : 12.85 (+0.16%)
EPZM : 1.4700 (-1.34%)
SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

RFP : 21.78 (+0.05%)
ZEN : 77.48 (+0.03%)
RDUS : 10.08 (-0.20%)
EPZM : 1.4700 (-1.34%)
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A....

EPZM : 1.4700 (-1.34%)
IPSEY : 25.8600 (-2.12%)
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ZEN, GRRB, EPZM

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

VIVO : 33.97 (unch)
ZEN : 77.48 (+0.03%)
EPZM : 1.4700 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar